Insiders · ALLO

ALLO insider transactions

Allogene Therapeutics Inc. (ALLO) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for ALLO

• 46d
  SVP, Finance Yoshiyama Annie sold $22,144 worth of shares (9,586 units at $2.31), decreasing direct ownership by 7% to 124,517 units (SEC Form 4) to satisfy withholding tax

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 67d
  SEC Form 4 filed by Beneski Benjamin Machinas

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 82d
  SEC Form 4 filed by Beneski Benjamin Machinas

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 82d
  SEC Form 4 filed by Chang David D

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 95d
  SVP, Chief Technical Officer Beneski Benjamin Machinas sold $18,543 worth of shares (7,132 units at $2.60), decreasing direct ownership by 3% to 203,040 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 123d
  SVP, Chief Technical Officer Beneski Benjamin Machinas sold $13,060 worth of shares (7,549 units at $1.73), decreasing direct ownership by 3% to 210,172 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 123d
  President and CEO Chang David D sold $171,484 worth of shares (95,269 units at $1.80), decreasing direct ownership by 2% to 5,185,862 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 123d
  CHIEF FINANCIAL OFFICER Parker Geoffrey M. sold $42,242 worth of shares (24,001 units at $1.76), decreasing direct ownership by 2% to 1,252,795 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 123d
  SVP, General Counsel Douglas Earl Martin sold $40,304 worth of shares (22,900 units at $1.76), decreasing direct ownership by 4% to 564,948 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 123d
  SVP, Finance Yoshiyama Annie sold $7,167 worth of shares (4,167 units at $1.72), decreasing direct ownership by 3% to 130,322 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 123d
  EVP of R&D Roberts Zachary sold $63,189 worth of shares (35,700 units at $1.77), decreasing direct ownership by 6% to 581,166 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 123d
  SEC Form 4 filed by Director Belldegrun Arie

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 135d
  EVP of R&D Roberts Zachary sold $40,980 worth of shares (26,269 units at $1.56), decreasing direct ownership by 4% to 616,866 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 167d
  Director Kazam Joshua A converted options into 47,700 shares, increasing direct ownership by 16% to 350,763 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 201d
  SVP, Chief Technical Officer Beneski Benjamin Machinas sold $959 worth of shares (786 units at $1.22), decreasing direct ownership by 0.36% to 217,721 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 227d
  CHIEF FINANCIAL OFFICER Parker Geoffrey M. sold $46,169 worth of shares (36,744 units at $1.26), decreasing direct ownership by 3% to 1,276,796 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 349d
  SEC Form 4 filed by Director Sato Vicki L

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 349d
  SEC Form 4 filed by Director Messemer Deborah M.

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 349d
  SEC Form 4 filed by Director Humer Franz B

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 349d
  SEC Form 4 filed by Director Barrett Elizabeth A.

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 349d
  SEC Form 4 filed by Director Witte Owen N.

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 349d
  SEC Form 4 filed by Director Mayo Stephen

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 349d
  SEC Form 4 filed by Director Kazam Joshua A

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 361d
  Director Messemer Deborah M. sold $52,377 worth of shares (36,885 units at $1.42), decreasing direct ownership by 26% to 107,431 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 410d
  SVP, Finance Yoshiyama Annie sold $13,537 worth of shares (9,601 units at $1.41), decreasing direct ownership by 7% to 130,663 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 446d
  President and CEO Chang David D sold $91,469 worth of shares (46,668 units at $1.96), decreasing direct ownership by 0.88% to 5,276,569 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 446d
  SVP, Chief Technical Officer Beneski Benjamin Machinas sold $10,839 worth of shares (5,488 units at $1.98), decreasing direct ownership by 2% to 218,507 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 459d
  SVP, Chief Technical Officer Beneski Benjamin Machinas was granted 31,755 shares, increasing direct ownership by 17% to 223,995 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 460d
  New insider Beneski Benjamin Machinas claimed ownership of 192,240 shares (SEC Form 3)

  3 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 472d
  Director Messemer Deborah M. sold $32,351 worth of shares (13,313 units at $2.43), decreasing direct ownership by 8% to 144,316 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 487d
  SVP, General Counsel Douglas Earl Martin sold $10,951 worth of shares (6,404 units at $1.71), decreasing direct ownership by 1% to 587,848 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 487d
  CHIEF FINANCIAL OFFICER Parker Geoffrey M. sold $7,545 worth of shares (4,361 units at $1.73), decreasing direct ownership by 0.33% to 1,301,540 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 487d
  Chief Technical Officer Moore Timothy L. sold $25,216 worth of shares (14,746 units at $1.71), decreasing direct ownership by 6% to 250,713 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 487d
  President and CEO Chang David D sold $77,285 worth of shares (46,003 units at $1.68), decreasing direct ownership by 0.86% to 5,317,237 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 487d
  EVP of R&D Roberts Zachary sold $32,014 worth of shares (18,832 units at $1.70), decreasing direct ownership by 3% to 643,135 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 495d
  SVP, General Counsel Douglas Earl Martin was granted 144,928 shares, increasing direct ownership by 32% to 594,252 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 495d
  CHIEF FINANCIAL OFFICER Parker Geoffrey M. was granted 173,913 shares, increasing direct ownership by 15% to 1,305,901 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 495d
  SVP, Finance Yoshiyama Annie was granted 36,232 shares, increasing direct ownership by 36% to 137,990 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 495d
  EVP of R&D Roberts Zachary was granted 173,913 shares, increasing direct ownership by 36% to 661,967 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 495d
  Director Belldegrun Arie was granted 369,957 shares, increasing direct ownership by 20% to 2,236,816 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 495d
  President and CEO Chang David D was granted 552,174 shares, increasing direct ownership by 11% to 5,363,240 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 500d
  EVP of R&D Roberts Zachary sold $48,414 worth of shares (27,199 units at $1.78), decreasing direct ownership by 5% to 488,054 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 544d
  Director Messemer Deborah M. sold $19,916 worth of shares (9,136 units at $2.18), decreasing direct ownership by 5% to 157,629 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 546d
  Director Humer Franz B sold $19,917 worth of shares (9,221 units at $2.16), decreasing direct ownership by 3% to 307,507 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 593d
  CHIEF FINANCIAL OFFICER Parker Geoffrey M. covered exercise/tax liability with 36,404 shares, decreasing direct ownership by 3% to 1,131,988 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 654d
  SVP, General Counsel Douglas Earl Martin covered exercise/tax liability with 28,310 shares, decreasing direct ownership by 6% to 449,324 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 718d
  Director Messemer Deborah M. sold $42,488 worth of shares (18,641 units at $2.28), decreasing direct ownership by 10% to 166,765 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 727d
  New insider Yoshiyama Annie claimed ownership of 101,758 shares (SEC Form 3)

  3 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 730d
  SEC Form 4 filed by Mayo Stephen

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 730d
  SEC Form 4 filed by Barrett Elizabeth A.

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 730d
  Sato Vicki L was granted 61,475 shares, increasing direct ownership by 61% to 162,575 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 730d
  Humer Franz B was granted 61,475 shares, increasing direct ownership by 24% to 316,728 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 730d
  SEC Form 4 filed by Witte Owen N.

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 730d
  SEC Form 4 filed by Kazam Joshua A

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 730d
  Messemer Deborah M. was granted 122,950 shares, increasing direct ownership by 197% to 185,406 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 735d
  Humer Franz B sold $26,181 worth of shares (11,200 units at $2.34), decreasing direct ownership by 4% to 255,253 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 748d
  Belldegrun Arie was granted 344,828 shares and bought $4,999,997 worth of shares (1,724,137 units at $2.90) (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 748d
  Parker Geoffrey M. was granted 344,828 shares, increasing direct ownership by 42% to 1,164,418 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 748d
  Chang David D was granted 344,828 shares, increasing direct ownership by 8% to 4,810,106 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
• 775d
  Moore Timothy L. covered exercise/tax liability with 17,360 shares, decreasing direct ownership by 6% to 265,459 units (SEC Form 4)

  4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)